Sfoglia per Autore
Proteasome inhibitors: Bortezomib in multiple myeloma
2008 Cavo M.; Pallotti M.C.; Pantani L.; Petrucci A.; Brioli A.; Terragna C.; Testoni N.; Marzocchi G.; Durante S.; Ceccolini M.; Perrone G.; Tacchetti P.; Zamagni E.; Tosi P.; Baccarani M.
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation.
2008 Tosi P; Terragna C; Testoni N; Zamagni E; Renzulli M; Tacchetti P; Montanari E; Perrone G; Ceccolini M; Brioli A; Pallotti MC; Tura S; Baccarani M; Cavo M.
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation
2009 Cavo M.; Zamagni E.; Tacchetti P.; Brioli A.; Pallotti C.; Pantani L.; Ceccolini M.; Petrucci A.; Testoni N.; Terragna C.; Marzocchi G.; Durante S.; Tosi P.; Baccarani M.
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
2009 Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M.
Thalidomide maintenance in multiple myeloma: certainties and controversies.
2009 Cavo M; Pantani L; Tacchetti P; Pallotti MC; Brioli A; Petrucci A; Zamagni E; Tosi P.
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
2010 Tosi P; Zamagni E; Tacchetti P; Ceccolini M; Perrone G; Brioli A; Pallotti MC; Pantani L; Petrucci A; Baccarani M; Cavo M.
Patient with ataxia telangiectasia who developed acute myeloid leukemia.
2011 Brioli A; Parisi S; Iacobucci I; Cavo M; Papayannidis C; Anna Zannetti B; Martinelli G; Baccarani M.
HIF 1 Alpha: A Suitable Target for Multiple Myeloma
2011 PERRONE G; BORSI E; TERRAGNA C; DURANTE S; MARTELLO M; ALUIGI M; MANCINI M; ZAMAGNI E; TACCHETTI P; BRIOLI A; PANTANI L; ZANNETTI BA; MARTINELLI G; SANTUCCI MA; BACCARANI M; CAVO M
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53
2011 TERRAGNA C; MARTELLO M; DURANTE S; PANTANI L; ZAMAGNI E; TACCHETTI P; BRIOLI A; PERRONE G; ZANNETTI BA; BORSI E; BACCARANI M; MARTINELLI G; CAVO M
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
2011 Zamagni E.; Brioli A.; Tacchetti P.; Zannetti B.; Pantani L.; Cavo M.
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease.
2012 Brioli A;Zamagni E;Pasquali S;Tosi P;Tacchetti P;Perrone G;Pantani L;Petrucci A;Zannetti BA;Baccarani M;Cavo M
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma.
2012 Zamagni E; Petrucci A; Tosi P; Tacchetti P; Perrone G; Brioli A; Pantani L; Zannetti B; Terragna C; Baccarani M; Cavo M.
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma
2012 Mancini; Elisa Leo; Elena Zamagni; Paola Tacchetti; Annamaria Brioli; Lucia Pantani; Beatrice Anna Zannetti; Giovanni Martinelli; Michele Cavo
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5
2012 Terragna, C; Martello, M; Martinelli, G; Durante, S; Pantani, L; Zamagni, E; Tacchetti, P; Brioli, A; Perrone, G; Zannetti, Ba; Borsi, E; Biasco, G; Baccarani, M; Cavo, M.
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53
2012 Terragna C; Martello M; Pantani L; Patriarca F; Zamagni E; Galli M; Tacchetti P; Petrucci MT; Crippa C; Bringhen S; Brioli A; Offidani M; Perrone G; Zannetti BA; Borsi E; Testoni N; Marzocchi G; Baccarani M; Martinelli G; Cavo M.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma.
2012 Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perrone G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A.
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.
2013 Brioli A;Boyd KD;Kaiser MF;Pawlyn C;Wu P;Gregory WM;Owen R;Ross FM;Jackson GH;Cavo M;Davies FE;Morgan GJ
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.
2013 Brioli A;Kaiser MF;Pawlyn C;Wu P;Gregory WM;Owen R;Ross FM;Jackson GH;Cavo M;Davies FE;Morgan GJ
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma
2013 Kaiser MF;Johnson DC;Wu P;Walker BA;Brioli A;Mirabella F;Wardell CP;Melchor L;Davies FE;Morgan GJ
The impact of response on bone-directed therapy in patients with multiple myeloma.
2013 Larocca A;Child JA;Cook G;Jackson GH;Russell N;Szubert A;Gregory WM;Brioli A;Owen RG;Drayson MT;Wu P;Palumbo A;Boccadoro M;Davies FE;Morgan GJ
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Proteasome inhibitors: Bortezomib in multiple myeloma | Cavo M.; Pallotti M.C.; Pantani L.; Petrucci A.; Brioli A.; Terragna C.; Testoni N.; Marzocchi G....; Durante S.; Ceccolini M.; Perrone G.; Tacchetti P.; Zamagni E.; Tosi P.; Baccarani M. | 2008-01-01 | HEMATOLOGY MEETING REPORTS | - | 1.01 Articolo in rivista | - |
| Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. | Tosi P; Terragna C; Testoni N; Zamagni E; Renzulli M; Tacchetti P; Montanari E; Perrone G; Ceccol...ini M; Brioli A; Pallotti MC; Tura S; Baccarani M; Cavo M. | 2008-01-01 | EUROPEAN JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation | Cavo M.; Zamagni E.; Tacchetti P.; Brioli A.; Pallotti C.; Pantani L.; Ceccolini M.; Petrucci A.;... Testoni N.; Terragna C.; Marzocchi G.; Durante S.; Tosi P.; Baccarani M. | 2009-01-01 | HEMATOLOGY MEETING REPORTS | - | 1.01 Articolo in rivista | - |
| Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. | Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda... A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M. | 2009-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Thalidomide maintenance in multiple myeloma: certainties and controversies. | Cavo M; Pantani L; Tacchetti P; Pallotti MC; Brioli A; Petrucci A; Zamagni E; Tosi P. | 2009-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.04 Replica / breve intervento (e simili) | - |
| Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. | Tosi P; Zamagni E; Tacchetti P; Ceccolini M; Perrone G; Brioli A; Pallotti MC; Pantani L; Petrucc...i A; Baccarani M; Cavo M. | 2010-01-01 | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Patient with ataxia telangiectasia who developed acute myeloid leukemia. | Brioli A; Parisi S; Iacobucci I; Cavo M; Papayannidis C; Anna Zannetti B; Martinelli G; Baccarani M. | 2011-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| HIF 1 Alpha: A Suitable Target for Multiple Myeloma | PERRONE G; BORSI E; TERRAGNA C; DURANTE S; MARTELLO M; ALUIGI M; MANCINI M; ZAMAGNI E; TACCHETTI ...P; BRIOLI A; PANTANI L; ZANNETTI BA; MARTINELLI G; SANTUCCI MA; BACCARANI M; CAVO M | 2011-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 | TERRAGNA C; MARTELLO M; DURANTE S; PANTANI L; ZAMAGNI E; TACCHETTI P; BRIOLI A; PERRONE G; ZANNET...TI BA; BORSI E; BACCARANI M; MARTINELLI G; CAVO M | 2011-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. | Zamagni E.; Brioli A.; Tacchetti P.; Zannetti B.; Pantani L.; Cavo M. | 2011-01-01 | SEMINARS IN THROMBOSIS AND HEMOSTASIS | - | 1.01 Articolo in rivista | - |
| Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. | Brioli A;Zamagni E;Pasquali S;Tosi P;Tacchetti P;Perrone G;Pantani L;Petrucci A;Zannetti BA;Bacca...rani M;Cavo M | 2012-01-01 | BONE MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. | Zamagni E; Petrucci A; Tosi P; Tacchetti P; Perrone G; Brioli A; Pantani L; Zannetti B; Terragna ...C; Baccarani M; Cavo M. | 2012-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma | Mancini; Elisa Leo; Elena Zamagni; Paola Tacchetti; Annamaria Brioli; Lucia Pantani; Beatrice Ann...a Zannetti; Giovanni Martinelli; Michele Cavo | 2012-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 | Terragna, C; Martello, M; Martinelli, G; Durante, S; Pantani, L; Zamagni, E; Tacchetti, P; Brioli..., A; Perrone, G; Zannetti, Ba; Borsi, E; Biasco, G; Baccarani, M; Cavo, M. | 2012-01-01 | CANCER RESEARCH | - | 4.02 Riassunto (Abstract) | - |
| High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 | Terragna C; Martello M; Pantani L; Patriarca F; Zamagni E; Galli M; Tacchetti P; Petrucci MT; Cri...ppa C; Bringhen S; Brioli A; Offidani M; Perrone G; Zannetti BA; Borsi E; Testoni N; Marzocchi G; Baccarani M; Martinelli G; Cavo M. | 2012-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. | Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perr...one G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A. | 2012-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy. | Brioli A;Boyd KD;Kaiser MF;Pawlyn C;Wu P;Gregory WM;Owen R;Ross FM;Jackson GH;Cavo M;Davies FE;Mo...rgan GJ | 2013-01-01 | BRITISH JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. | Brioli A;Kaiser MF;Pawlyn C;Wu P;Gregory WM;Owen R;Ross FM;Jackson GH;Cavo M;Davies FE;Morgan GJ | 2013-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma | Kaiser MF;Johnson DC;Wu P;Walker BA;Brioli A;Mirabella F;Wardell CP;Melchor L;Davies FE;Morgan GJ | 2013-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| The impact of response on bone-directed therapy in patients with multiple myeloma. | Larocca A;Child JA;Cook G;Jackson GH;Russell N;Szubert A;Gregory WM;Brioli A;Owen RG;Drayson MT;W...u P;Palumbo A;Boccadoro M;Davies FE;Morgan GJ | 2013-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile